ReviewEye (London, England)2023
Perspectives of diabetic retinopathy-challenges and opportunities.
Review in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- A hybrid CNN-GNN and multitask learning pipeline for improving mild diabetic retinopathy sensitivity.MethodsX · 2026Article
- The role and mechanism of the miR-137 regulatory axis in diabetic retinopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Article
- Human single-cell atlas of proliferative diabetic retinopathy reveals a SOX15-overexpressing stromal population driving retinal fibrosis through the endothelin-1 -EDNRB axis.Journal of translational medicine · 2026Article
- Endothelial dysfunction in human diabetic vascular complications: translating single-cell transcriptomics into therapeutic opportunities.Molecular medicine (Cambridge, Mass.) · 2026Review
- Identification and analysis of oxidative stress-related genes associated with the occurrence and development of diabetic retinopathy.Scientific reports · 2026Article
- Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy (RIC-NPDR): study protocol for a randomized controlled trial.BMC complementary medicine and therapies · 2026Article
- Comparative analysis of activation of macrophages/microglia in diabetic retinopathy and Familial Exudative Vitreoretinopathy.Biochemistry and biophysics reports · 2026Article
- Progress in the Cross-Organ Biomarker oxLDL in Promoting Pathological Neovascular Diseases.Antioxidants (Basel, Switzerland) · 2026Review
- [Quantitative Assessment of Microvascular Changes in Diabetic Retinopathy and Their Association With Blood-Retinal Barrier Impairment].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- Management of diabetic macular edema: from anti-VEGF to emerging therapies.Frontiers in medicine · 2026Review
- Angiogenesis-RNA modification in diabetic retinopathy: biomarkers and targets.International journal of ophthalmology · 2026Article
- Associations between sleep patterns and diabetic retinopathy: insights from cross-sectional and longitudinal evidence.Eye (London, England) · 2025Article
- Leucine-rich α-2-glycoprotein 1 initiates the onset of diabetic retinopathy in mice.Science translational medicine · 2025Article
- Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.Materials today. Bio · 2025Review
- Potential mechanisms of epigenetic regulation in diabetic retinopathy from the perspectives of multi-omics.Diabetology & metabolic syndrome · 2025Article
- Sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic macular edema and the need for intravitreal injection.International journal of ophthalmology · 2025Article
- Proteomic Analysis of Retinas in a Rat Model of High-Fat Diet-Induced Type 2 Diabetes: Implications of Interventional Targets for Nonproliferative Diabetic Retinopathy.Drug design, development and therapy · 2025Article
- A panoramic perspective: application prospects and outlook of multimodal artificial intelligence in the management of diabetic retinopathy.Frontiers in public health · 2025Review
- Comparison of Widefield OCT Angiography Features Between Severe Non-Proliferative and Proliferative Diabetic Retinopathy.Ophthalmology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
Abstract
Diabetic retinopathy (DR) may lead to vision-threatening complications in people living with diabetes mellitus. Decades of research have contributed to our understanding of the pathogenesis of diabetic retinopathy from non-proliferative to proliferative (PDR) stages, the occurrence of diabetic macular oedema (DMO) and response to various treatment options. Multimodal imaging has paved the way to predict the impact of peripheral lesions and optical coherence tomography-angiography is starting to provide new knowledge on diabetic macular ischaemia. Moreover, the availability of intravitreal anti-vascular endothelial growth factors has changed the treatment paradigm of DMO and PDR. Areas of research have explored mechanisms of breakdown of the blood-retinal barrier, damage to pericytes, the extent of capillary non-perfusion, leakage and progression to neovascularisation. However, knowledge gaps remain. From this perspective, we highlight the challenges and future directions of research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.